Clara Di Mario
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clara Di Mario has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Tolusso
Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, 00168 Rome, Italy
7 shared publications - Elisa Gremese
Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
6 shared publications - Maria Rita Gigante
Fondazione Policlinico Universitario A. Gemelli IRCCS, Division of Rheumatology, Rome, Italy
6 shared publications - Luca Petricca
Fondazione Policlinico Universitario A. Gemelli IRCCS, Division of Rheumatology, Rome, Italy
5 shared publications - Stefano Alivernini
Division of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario A. Gemelli IRCCS Rome, Rome, Italy
5 shared publications - Dario Bruno
Immunology and Rheumatology Unit, IRCCS Humanitas Research Hospital , Milan
4 shared publications
Latest Publications
- Open Access
Distinct tissue-niche localization and function of synovial tissue myeloid DC subsets in health, and in active and remission Rheumatoid Arthritis
Summary: Current rheumatoid arthritis (RA) treatments do not restore immune tolerance. Investigating dendritic cell (DC) populations in human synovial tissue (ST) may reveal pathways to re-instate tolerance in RA. With single-cell and spatial-transcriptomics of synovial tissue biopsies, validated by micro co-culture systems, we identified condition and niche-specific myeloid DC clusters with distinct differentiation trajectories and functions. Healthy synovium contains a unique tolerogenic AXL pos DC2 cluster in the superficial sublining layer. In active RA, a macrophage-rich lining-layer niche becomes populated with inflammatory DC3 clusters that specifically activate memory CCL5 pos TEM and CCL5 pos CXCL13 pos TPH, promoting synovitis. In the sublining lymphoid niche, CCR7 pos DC2 mReg specifically interact with naïve-T-cells, potentially driving the local expansion of new effector T-cells. Sustained remission sees the resolution of these niches but lacks the recovery of tolerogenic AXL pos DC2, indicating latent potential for disease flare. A human RA disease-flare model showed that the activation of blood predecessor of ST-DC3 clusters precedes the onset of inflammation in joints. Therapeutic strategies targeting pathogenic ST-DC3 clusters, or reinstating tolerogenic AXL pos DC2, may restore immune homeostasis in RA. In brief: Deconstruction of human RA synovium, using single-cell spatial transcriptomics and micro-culture systems, reveals distinct neighbourhoods within the synovial architecture across health, and RA patients with active disease or sustained remission. Discrete niches are identified that contain distinct myeloid DC clusters that differ in frequency, differentiation trajectories, and effector functions. Highlights: Human RA synovium exhibits condition and niche specific myeloid DC clusters that vary in their tissue differentiation trajectories and functions. ST-CD14 pos DC3 (iDC3) support inflammatory CCL5 pos TEM and CCL5 pos TPH cell activation in the hyperplastic lining layer. ST-CCR7 pos DC2 (mReg), driven by MIR155, interact with naïve-T-cells in sublining lymphoid niches. A specific inflammatory signature of blood predecessors of ST-DC3s predict flare in RA. Graphical
Open AccessDistinct tissue-niche localization and function of synovial tissue myeloid DC subsets in health, and in active and remission Rheumatoid Arthritis
Summary: Current rheumatoid arthritis (RA) treatments do not restore immune tolerance. Investigating dendritic cell (DC) populations in human synovial tissue (ST) may reveal pathways to re-instate tolerance in RA. With single-cell and spatial-transcriptomics of synovial tissue biopsies, validated by micro co-culture systems, we identified condition and niche-specific myeloid DC clusters with distinct differentiation trajectories and functions. Healthy synovium contains a unique tolerogenic AXL pos DC2 cluster in the superficial sublining layer. In active RA, a macrophage-rich lining-layer niche becomes populated with inflammatory DC3 clusters that specifically activate memory CCL5 pos TEM and CCL5 pos CXCL13 pos TPH, promoting synovitis. In the sublining lymphoid niche, CCR7 pos DC2 mReg specifically interact with naïve-T-cells, potentially driving the local expansion of new effector T-cells. Sustained remission sees the resolution of these niches but lacks the recovery of tolerogenic AXL pos DC2, indicating latent potential for disease flare. A human RA disease-flare model showed that the activation of blood predecessor of ST-DC3 clusters precedes the onset of inflammation in joints. Therapeutic strategies targeting pathogenic ST-DC3 clusters, or reinstating tolerogenic AXL pos DC2, may restore immune homeostasis in RA. In brief: Deconstruction of human RA synovium, using single-cell spatial transcriptomics and micro-culture systems, reveals distinct neighbourhoods within the synovial architecture across health, and RA patients with active disease or sustained remission. Discrete niches are identified that contain distinct myeloid DC clusters that differ in frequency, differentiation trajectories, and effector functions. Highlights: Human RA synovium exhibits condition and niche specific myeloid DC clusters that vary in their tissue differentiation trajectories and functions. ST-CD14 pos DC3 (iDC3) support inflammatory CCL5 pos TEM and CCL5 pos TPH cell activation in the hyperplastic lining layer. ST-CCR7 pos DC2 (mReg), driven by MIR155, interact with naïve-T-cells in sublining lymphoid niches. A specific inflammatory signature of blood predecessors of ST-DC3s predict flare in RA. Graphical
- Open Access
- 7 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 1028
POS1353 SEMIQUANTITATIVE ASSESSMENT OF KNEE OSTEOARTHRITIS-RELATED SYNOVITIS COMPARED TO CHRONIC INFLAMMATORY ARTHRITIDES: RELATION TO AGE AND IMPACT ON BONE/STRUCTURAL DAMAGE
Background Knee Osteoarthritis (KOA) is one of the most frequent causes of pain and disability, representing a relevant clinical burden. Although it was largely considered a mostly mechanical-based pathology, low-grade synovial inflammation was found to contribute to radiographic progression and pain chronicity [1]. Objectives To evaluate the histological characteristics of synovial membrane inflammation in KOA patients compared to chronic inflammatory diseases as Rheumatoid (RA) and Psoriatic Arthritis (PsA) across disease phases. Methods 170 patients with KOA, 240 patients with RA, 92 patients with PsA naive to pharmacological treatments and 200 patients with RA in sustained clinical and ultrasound remission (RA-r) underwent ultrasound-guided synovial biopsy of the knee and conventional X-rays. None of enrolled KOA patient had evidence of inflammatory condition (including chronic inflammatory diseases and crystal related arthritis). Synovial membrane samples were processed for histology (hematoxylin-eosin staining) for the semiquantitative assessment of synovitis degree (Krenn synovitis score [2] - KSS). Moreover, this analysis was implemented with the semiqualitative assessment of presence/absence of synovial lymphocytes, plasmacells, myxoid degeneration and inflammatory perivascular aggregates. X-rays were scored for Kellgren-Lawrence score [3] (KLs) assessment. Results RA and PsA patients naive to pharmacological treatment showed higher degree of synovial inflammation than patients with KOA as well as more likely presence of lymphocytes and plasmacells aggregates. Considering the whole KOA population, total KSS directly correlated with age (R²=0.041; p=0.008), thickness of synovial membrane (R²=0.115; pConclusion KOA-related synovitis represents an unmet clinical need due to still uncovered pathogenetic mechanisms. The severity of KOA-related synovitis impacts on bone structural damage and is related to age, supporting the role of inflammageing in KOA pathogenesis. References [1]Sanchez-Lopez, E., Coras, R., Torres, A., Lane, N. E. & Guma, M. Synovial inflammation in osteoarthritis progression. Nature Reviews Rheumatology vol. 18 Preprint at https://doi.org/10.1038/s41584-022-00749-9 (2022). [2]Krenn, V. et al. Synovitis score: Discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, (2006). [3]KELLGREN, J. H. & LAWRENCE, J. S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16, (1957). Acknowledgements: NIL. Disclosure of Interests None Declared.
- 7 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 1028
Open AccessPOS1353 SEMIQUANTITATIVE ASSESSMENT OF KNEE OSTEOARTHRITIS-RELATED SYNOVITIS COMPARED TO CHRONIC INFLAMMATORY ARTHRITIDES: RELATION TO AGE AND IMPACT ON BONE/STRUCTURAL DAMAGE
Background Knee Osteoarthritis (KOA) is one of the most frequent causes of pain and disability, representing a relevant clinical burden. Although it was largely considered a mostly mechanical-based pathology, low-grade synovial inflammation was found to contribute to radiographic progression and pain chronicity [1]. Objectives To evaluate the histological characteristics of synovial membrane inflammation in KOA patients compared to chronic inflammatory diseases as Rheumatoid (RA) and Psoriatic Arthritis (PsA) across disease phases. Methods 170 patients with KOA, 240 patients with RA, 92 patients with PsA naive to pharmacological treatments and 200 patients with RA in sustained clinical and ultrasound remission (RA-r) underwent ultrasound-guided synovial biopsy of the knee and conventional X-rays. None of enrolled KOA patient had evidence of inflammatory condition (including chronic inflammatory diseases and crystal related arthritis). Synovial membrane samples were processed for histology (hematoxylin-eosin staining) for the semiquantitative assessment of synovitis degree (Krenn synovitis score [2] - KSS). Moreover, this analysis was implemented with the semiqualitative assessment of presence/absence of synovial lymphocytes, plasmacells, myxoid degeneration and inflammatory perivascular aggregates. X-rays were scored for Kellgren-Lawrence score [3] (KLs) assessment. Results RA and PsA patients naive to pharmacological treatment showed higher degree of synovial inflammation than patients with KOA as well as more likely presence of lymphocytes and plasmacells aggregates. Considering the whole KOA population, total KSS directly correlated with age (R²=0.041; p=0.008), thickness of synovial membrane (R²=0.115; pConclusion KOA-related synovitis represents an unmet clinical need due to still uncovered pathogenetic mechanisms. The severity of KOA-related synovitis impacts on bone structural damage and is related to age, supporting the role of inflammageing in KOA pathogenesis. References [1]Sanchez-Lopez, E., Coras, R., Torres, A., Lane, N. E. & Guma, M. Synovial inflammation in osteoarthritis progression. Nature Reviews Rheumatology vol. 18 Preprint at https://doi.org/10.1038/s41584-022-00749-9 (2022). [2]Krenn, V. et al. Synovitis score: Discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, (2006). [3]KELLGREN, J. H. & LAWRENCE, J. S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16, (1957). Acknowledgements: NIL. Disclosure of Interests None Declared.
- Open Access
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 943-944
SAT0027 DEVELOPMENT AND VALIDATION OF A NOMOGRAM COMBINING CLINICAL AND HISTOPATHOLOGICAL SYNOVIAL FEATURES FOR PREDICTING EARLY TREATMENT RESPONSE IN NAIVE TO TREATMENT RHEUMATOID ARTHRITIS
Background: Rheumatoid Arthritis (RA) is characterized by synovial tissue (ST) heterogeneity at disease onset in terms of inflammatory degree and microanatomical organization being related to treatment response. Objectives: To develop a multiparametric tool for baseline treatment response prediction including disease characteristics and histopathologic features of ST biopsies, using a large single center (SYNGem Unit) naive to treatment RA cohort. Methods: 240 naive to treatment RA who underwent US-guided ST biopsy, at the first clinical evaluation, were enrolled. Clinical and immunological characteristics were recorded for each patient. All ST FFPE specimens were stained with H&E and classified by a pathologist, blinded to clinical characteristics, using the Krenn score [1] to assess the degree of ST inflammation. All naive to treatment RA were treated according to the T2T scheme and DAS remission rate at 6-12 months was recorded. On the basis of the regression analysis, a nomogram was constructed that incorporated the significant factors predicting the “achievement of DAS-Remission at 6 months follow-up” in naive RA. The performance of the nomogram was assessed by discrimination and calibration. Results: Univariate analysis showed that RA who achieved early (6 months) DAS-remission had, at baseline, significantly lower total Krenn score (pConclusion: Krenn score is a reliable tool for the semi-quantitative assessment of ST inflammation on US-guided ST biopsies being contingent to baseline disease characteristics and can be integrated within a nomogram to better predict the therapeutic response in naive to treatment RA. References: [1] Krenn V, et al. Histopathology 2006 Disclosure of Interests: Stefano Alivernini: None declared, Barbara Tolusso: None declared, Marco Gessi: None declared, Maria Rita Gigante: None declared, Alice Mannocci: None declared, Luca Petricca: None declared, Simone Perniola: None declared, Clara Di Mario: None declared, Anna Laura Fedele: None declared, Laura Bui: None declared, Annunziata Capacci: None declared, Dario Bruno: None declared, Giuseppe La Torre: None declared, Francesco Federico: None declared, Gianfranco Ferraccioli: None declared, Elisa Gremese Speakers bureau: Abbvie, BMS, Celgene, Jannsen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 943-944
Open AccessSAT0027 DEVELOPMENT AND VALIDATION OF A NOMOGRAM COMBINING CLINICAL AND HISTOPATHOLOGICAL SYNOVIAL FEATURES FOR PREDICTING EARLY TREATMENT RESPONSE IN NAIVE TO TREATMENT RHEUMATOID ARTHRITIS
Background: Rheumatoid Arthritis (RA) is characterized by synovial tissue (ST) heterogeneity at disease onset in terms of inflammatory degree and microanatomical organization being related to treatment response. Objectives: To develop a multiparametric tool for baseline treatment response prediction including disease characteristics and histopathologic features of ST biopsies, using a large single center (SYNGem Unit) naive to treatment RA cohort. Methods: 240 naive to treatment RA who underwent US-guided ST biopsy, at the first clinical evaluation, were enrolled. Clinical and immunological characteristics were recorded for each patient. All ST FFPE specimens were stained with H&E and classified by a pathologist, blinded to clinical characteristics, using the Krenn score [1] to assess the degree of ST inflammation. All naive to treatment RA were treated according to the T2T scheme and DAS remission rate at 6-12 months was recorded. On the basis of the regression analysis, a nomogram was constructed that incorporated the significant factors predicting the “achievement of DAS-Remission at 6 months follow-up” in naive RA. The performance of the nomogram was assessed by discrimination and calibration. Results: Univariate analysis showed that RA who achieved early (6 months) DAS-remission had, at baseline, significantly lower total Krenn score (pConclusion: Krenn score is a reliable tool for the semi-quantitative assessment of ST inflammation on US-guided ST biopsies being contingent to baseline disease characteristics and can be integrated within a nomogram to better predict the therapeutic response in naive to treatment RA. References: [1] Krenn V, et al. Histopathology 2006 Disclosure of Interests: Stefano Alivernini: None declared, Barbara Tolusso: None declared, Marco Gessi: None declared, Maria Rita Gigante: None declared, Alice Mannocci: None declared, Luca Petricca: None declared, Simone Perniola: None declared, Clara Di Mario: None declared, Anna Laura Fedele: None declared, Laura Bui: None declared, Annunziata Capacci: None declared, Dario Bruno: None declared, Giuseppe La Torre: None declared, Francesco Federico: None declared, Gianfranco Ferraccioli: None declared, Elisa Gremese Speakers bureau: Abbvie, BMS, Celgene, Jannsen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB
- Open Access
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1055
SAT0224 ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS
Background: Several studies have showed that antiphospholipid antibodies (aPL) positivity represents a predictor of worse renal outcome in patients with Lupus Nephritis (LN). In addition, an association between aPL positivity and the histological data of vascular lesions on the renal biopsies has been reported. Objectives: To determine the prognostic role of aPL and vascular renal lesions in the assessment of clinical outcome during the follow up period, in terms of time to achieve remission, number of renal flares and development of chronic renal damage in patients affected by LN. Methods: Among 120 patients affected by LN from our Rheumatology Unit, 91 patients (age 43.8 ± 12 years, 74 (81.3%) female, disease duration 7.1 ± 7.9 years) have been evaluated and the follow-up data have been collected at the baseline and at 6, 12, 24 months and at the last follow-up visit. Histopathological data of 41 patients were evaluated according to the 2016 revision of ISN/RPS classification. Results: Among the 91 LN patients, 31 (34.1%) were aPL positive (aPL+), 10 (32.2%) of them were affected by Antiphospholipid Antibodies Syndrome (APS), 53.3% showed a single aPL positivity, 23.1% double aPL positivity and 15.4% triple aPL positivity. At the last follow up visit a significant higher number of aPL+ patients showed a persistent complement consumption than aPL negative (aPL-) patients (p=0.001). Evaluating clinical outcome, we observed that aPL- patients showed a remission achievement time slightly earlier than aPL+ patients (13.6 ± 1.0 months vs 16.5 ± 1.5 months; log-rank test: p=0.06, Breslow test: p=0.08) and as expected, patients with a persistent complement consumption achieve remission later (18.2 ± 1.5 months vs 13.0 ± 1 months; log-rank test: p=0.002, Breslow test: p=0.003). Furthermore at the last follow up, a significant higher percentage of aPL+ patients developed persistent proteinuria (p=0.02) and chronic renal failure (p=0.04). Considering histologic features (activity and chronicity index, glomerulonephritis class, presence of mesangiolysis, glomerular wrinkling, glomerular thrombi, interstitial inflammatory infiltrates, interstitial fibrosis and tubular atrophy,tubulitis and vascular lesions) we didn’t observe significant differences between aPL+ and aPL- patients but we found two typical vascular lesions (mesangiolysis and vascular thrombi) only in aPL + patients. Conclusion: aPL positivity is a predictor of worse renal outcome but in our cohort of LN patients we didn’t find an association between aPL positivity and vascular renal lesions at renal biopsy. The worse renal outcome and the late time to achieve remission in aPL+ group can be related to a cumulative vascular damage over time as observed in other organ and systems. Disclosure of Interests: None declared
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1055
Open AccessSAT0224 ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS
Background: Several studies have showed that antiphospholipid antibodies (aPL) positivity represents a predictor of worse renal outcome in patients with Lupus Nephritis (LN). In addition, an association between aPL positivity and the histological data of vascular lesions on the renal biopsies has been reported. Objectives: To determine the prognostic role of aPL and vascular renal lesions in the assessment of clinical outcome during the follow up period, in terms of time to achieve remission, number of renal flares and development of chronic renal damage in patients affected by LN. Methods: Among 120 patients affected by LN from our Rheumatology Unit, 91 patients (age 43.8 ± 12 years, 74 (81.3%) female, disease duration 7.1 ± 7.9 years) have been evaluated and the follow-up data have been collected at the baseline and at 6, 12, 24 months and at the last follow-up visit. Histopathological data of 41 patients were evaluated according to the 2016 revision of ISN/RPS classification. Results: Among the 91 LN patients, 31 (34.1%) were aPL positive (aPL+), 10 (32.2%) of them were affected by Antiphospholipid Antibodies Syndrome (APS), 53.3% showed a single aPL positivity, 23.1% double aPL positivity and 15.4% triple aPL positivity. At the last follow up visit a significant higher number of aPL+ patients showed a persistent complement consumption than aPL negative (aPL-) patients (p=0.001). Evaluating clinical outcome, we observed that aPL- patients showed a remission achievement time slightly earlier than aPL+ patients (13.6 ± 1.0 months vs 16.5 ± 1.5 months; log-rank test: p=0.06, Breslow test: p=0.08) and as expected, patients with a persistent complement consumption achieve remission later (18.2 ± 1.5 months vs 13.0 ± 1 months; log-rank test: p=0.002, Breslow test: p=0.003). Furthermore at the last follow up, a significant higher percentage of aPL+ patients developed persistent proteinuria (p=0.02) and chronic renal failure (p=0.04). Considering histologic features (activity and chronicity index, glomerulonephritis class, presence of mesangiolysis, glomerular wrinkling, glomerular thrombi, interstitial inflammatory infiltrates, interstitial fibrosis and tubular atrophy,tubulitis and vascular lesions) we didn’t observe significant differences between aPL+ and aPL- patients but we found two typical vascular lesions (mesangiolysis and vascular thrombi) only in aPL + patients. Conclusion: aPL positivity is a predictor of worse renal outcome but in our cohort of LN patients we didn’t find an association between aPL positivity and vascular renal lesions at renal biopsy. The worse renal outcome and the late time to achieve remission in aPL+ group can be related to a cumulative vascular damage over time as observed in other organ and systems. Disclosure of Interests: None declared
- Open Access
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1908
AB1234 MICRO-RNA 155 AND MIR-34A: POSSIBLE BIOMARKERS OF INFLAMMATORY BURDEN AND DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS WITH RENAL INVOLVEMENT
Background: Predicting clinical outcomes in ANCA-related glomerulonephritis remains a major challenge. To date, there is no reliable biomarker able to predict renal prognosis in patients with ANCA-associated vasculitis (AAV). Micro-RNA (miRNA) are non-coding RNAs involved in the fine tuning of immune cells biology and this epigenetic modulation associates with different phenotypes and prognosis in several diseases. Objectives: To investigate the expression of miR-155 and miR-34a in kidney biopsies of AAV patients according with renal outcome. Methods: Fifteen patients with AAV and renal involvement (mean age 63.0 ±13.3 years, disease duration 4.9±2.2 months), who underwent renal biopsy. Demographic, clinical and autoimmune parameters were recorded for each patient. Each kidney biopsy was classified according to the Berden Classification, Risk group (according to the ANCA Renal Risk Score) and the chronicity Classification of the Mayo Clinic’s proposed score. MiR-155 and miR-34a expression was investigated on kidney biopsy tissue using the miRNeasy FFPE kit (Qiagen). The quantitative expression of miR-155, miR-34a and housekeeping gene U1, used as control, was assessed by Real Time-PCR. MiR-155 and miR-34a expression was correlated with histopathological and clinical-laboratory parameters. Each patient was followed for 12 months and renal outcome was considered according to KDIGO CKD Classification. Markers of inflammation (ESR, CRP) and urine analysis data were recorded at baseline and after 12 months. Results: Six (40%) patients were p-ANCA positive and 9 (60%) c-ANCA positive. Eight patients (53%) also had pulmonary involvement. The mean baseline GFR was 30.7±28.8 ml/min/1.73 m2 and 10 patients (66%) showed an active urinary sediment. At disease onset, the mean expression of miR-155 was 9.5±21.1, while the expression of mir-34a was 13.1±46.2. Considering the autoimmune profile, kidney tissue of p-ANCA positive patients was enriched of mir-155 (19.6±30.6 fold) compared to c-ANCA positive patients (1.9±2.9 fold; p=0.001). Particularly, considering the renal function, kidney tissue of patients with greater impairment of renal function (KDIGO stage 5) was enriched of miR-155 (21.5±38.3 fold) compared to patients with less renal impairment (KDIGO stage 1-4) (4.72±8.16 fold, p=0.004). Tissue expression of miR-155 and miR-34a did not correlated with the abovementioned histopathological classifications. After 12 months from kidney biopsy, 3(20%) patients had a worsening of renal function, 5 (33%) still presented elevated markers of inflammation and 3 (20%) still had proteinuria at urine analysis. At baseline, kidney tissue of patients with higher CRP plasma levels and proteinuria at follow-up presented higher expression of miR-155 (p=0.002 and p=0.001), whereas no significant differences were found about miR-34a kidney tissue expression. Conclusion: MiRNAs may play a potential role in the pathogenesis of ANCA-related glomerulonephritis. MiR-155 kidney enrichment seems to mirror the disease inflammatory burden and activity at the onset and after 12 months representing a possible biomarker in ANCA vasculitis with renal involvement. This finding may represent the basis for further studies on miRNA expression in blood samples, aiming to identify a non-invasive biomarker of kidney damage, predicting disease’s relapses and patients’ prognosis. References: [1]Renauer et al, Clin Rev Allergy Immunol. 2016 Disclosure of Interests: Dario Bruno: None declared, Pier Giacomo Cerasuolo: None declared, Clara Di Mario: None declared, Silvia Laura Bosello Speakers bureau: Abbvie, Pfizer, Boehringer, Laura Gigante: None declared, Alessia Musto: None declared, Gisella Vischini: None declared, Stefano Costanzi: None declared, Stefano Alivernini: None declared, Barbara Tolusso: None declared, Giuseppe Grandaliano: None declared, Elisa Gremese Speakers bureau: Abbvie, BMS, Celgene, Jannsen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1908
Open AccessAB1234 MICRO-RNA 155 AND MIR-34A: POSSIBLE BIOMARKERS OF INFLAMMATORY BURDEN AND DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS WITH RENAL INVOLVEMENT
Background: Predicting clinical outcomes in ANCA-related glomerulonephritis remains a major challenge. To date, there is no reliable biomarker able to predict renal prognosis in patients with ANCA-associated vasculitis (AAV). Micro-RNA (miRNA) are non-coding RNAs involved in the fine tuning of immune cells biology and this epigenetic modulation associates with different phenotypes and prognosis in several diseases. Objectives: To investigate the expression of miR-155 and miR-34a in kidney biopsies of AAV patients according with renal outcome. Methods: Fifteen patients with AAV and renal involvement (mean age 63.0 ±13.3 years, disease duration 4.9±2.2 months), who underwent renal biopsy. Demographic, clinical and autoimmune parameters were recorded for each patient. Each kidney biopsy was classified according to the Berden Classification, Risk group (according to the ANCA Renal Risk Score) and the chronicity Classification of the Mayo Clinic’s proposed score. MiR-155 and miR-34a expression was investigated on kidney biopsy tissue using the miRNeasy FFPE kit (Qiagen). The quantitative expression of miR-155, miR-34a and housekeeping gene U1, used as control, was assessed by Real Time-PCR. MiR-155 and miR-34a expression was correlated with histopathological and clinical-laboratory parameters. Each patient was followed for 12 months and renal outcome was considered according to KDIGO CKD Classification. Markers of inflammation (ESR, CRP) and urine analysis data were recorded at baseline and after 12 months. Results: Six (40%) patients were p-ANCA positive and 9 (60%) c-ANCA positive. Eight patients (53%) also had pulmonary involvement. The mean baseline GFR was 30.7±28.8 ml/min/1.73 m2 and 10 patients (66%) showed an active urinary sediment. At disease onset, the mean expression of miR-155 was 9.5±21.1, while the expression of mir-34a was 13.1±46.2. Considering the autoimmune profile, kidney tissue of p-ANCA positive patients was enriched of mir-155 (19.6±30.6 fold) compared to c-ANCA positive patients (1.9±2.9 fold; p=0.001). Particularly, considering the renal function, kidney tissue of patients with greater impairment of renal function (KDIGO stage 5) was enriched of miR-155 (21.5±38.3 fold) compared to patients with less renal impairment (KDIGO stage 1-4) (4.72±8.16 fold, p=0.004). Tissue expression of miR-155 and miR-34a did not correlated with the abovementioned histopathological classifications. After 12 months from kidney biopsy, 3(20%) patients had a worsening of renal function, 5 (33%) still presented elevated markers of inflammation and 3 (20%) still had proteinuria at urine analysis. At baseline, kidney tissue of patients with higher CRP plasma levels and proteinuria at follow-up presented higher expression of miR-155 (p=0.002 and p=0.001), whereas no significant differences were found about miR-34a kidney tissue expression. Conclusion: MiRNAs may play a potential role in the pathogenesis of ANCA-related glomerulonephritis. MiR-155 kidney enrichment seems to mirror the disease inflammatory burden and activity at the onset and after 12 months representing a possible biomarker in ANCA vasculitis with renal involvement. This finding may represent the basis for further studies on miRNA expression in blood samples, aiming to identify a non-invasive biomarker of kidney damage, predicting disease’s relapses and patients’ prognosis. References: [1]Renauer et al, Clin Rev Allergy Immunol. 2016 Disclosure of Interests: Dario Bruno: None declared, Pier Giacomo Cerasuolo: None declared, Clara Di Mario: None declared, Silvia Laura Bosello Speakers bureau: Abbvie, Pfizer, Boehringer, Laura Gigante: None declared, Alessia Musto: None declared, Gisella Vischini: None declared, Stefano Costanzi: None declared, Stefano Alivernini: None declared, Barbara Tolusso: None declared, Giuseppe Grandaliano: None declared, Elisa Gremese Speakers bureau: Abbvie, BMS, Celgene, Jannsen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB
- Open Access
- 23 March 2020
- Published by BMJ
- Vol. 7 (Suppl 1) , A123.2-A123
P192 Evaluation of predictive factors of worse prognosis in lupus nephritis: focus on new pathogenetic pathways
Purpose To evaluate the prognostic factors in a cohort of patients with lupus nephritis (LN) focusing on of the IL-17, 23 axis as new pathogenetic pathway. Patients and Methods 91 LN patients were enrolled. Laboratory, immunological and disease activity data were collected at the baseline and at 6(T6),12(T12),24(T24) months and at the last follow-up(FU).84 renal biopsies were evaluated according to ISN/RPS classification, assessing the inflammatory interstitial infiltrate using the BANFF score. Baseline serum levels of IL-17 and IL-23 were assessed by ELISA in 37 patients. Results Among the 84 renal biopsies evaluated 77% belonged to class III and IV; 41,8% of patients had an interstitial infiltrate5% at renal biopsy and persistent proteinuria. Finally, we conducted an univariate and multivariate analysis for each renal outcome considered. We found that an inflammatory interstitial infiltrate>5% and APL+ were associated with worse renal outcome in terms of early and persistent remission, chronic damage, persistent proteinuria, and renal flare both in univariate and multivariate analysis. Higher serum level of IL-23 was associated with persistent proteinuria, renal flare and tended to be associated to chronic renal damage. Conclusion Interstitial infiltrate and APL+ resulted as the strongest predictors of worse renal outcome. An higher serum level of IL-23 resulted as a negative prognostic factor highlighting its possible role as a biomarkers of more aggressive disease.
- 23 March 2020
- Published by BMJ
- Vol. 7 (Suppl 1) , A123.2-A123
Open AccessP192 Evaluation of predictive factors of worse prognosis in lupus nephritis: focus on new pathogenetic pathways
Purpose To evaluate the prognostic factors in a cohort of patients with lupus nephritis (LN) focusing on of the IL-17, 23 axis as new pathogenetic pathway. Patients and Methods 91 LN patients were enrolled. Laboratory, immunological and disease activity data were collected at the baseline and at 6(T6),12(T12),24(T24) months and at the last follow-up(FU).84 renal biopsies were evaluated according to ISN/RPS classification, assessing the inflammatory interstitial infiltrate using the BANFF score. Baseline serum levels of IL-17 and IL-23 were assessed by ELISA in 37 patients. Results Among the 84 renal biopsies evaluated 77% belonged to class III and IV; 41,8% of patients had an interstitial infiltrate5% at renal biopsy and persistent proteinuria. Finally, we conducted an univariate and multivariate analysis for each renal outcome considered. We found that an inflammatory interstitial infiltrate>5% and APL+ were associated with worse renal outcome in terms of early and persistent remission, chronic damage, persistent proteinuria, and renal flare both in univariate and multivariate analysis. Higher serum level of IL-23 was associated with persistent proteinuria, renal flare and tended to be associated to chronic renal damage. Conclusion Interstitial infiltrate and APL+ resulted as the strongest predictors of worse renal outcome. An higher serum level of IL-23 resulted as a negative prognostic factor highlighting its possible role as a biomarkers of more aggressive disease.
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 352
THU0488 Microrna-34A and Microrna-155 Unbalance is Associated to IL-6/IL-6R and Vegf/Vegf-Rii Pathways in VEDOSS and Long Standing Systemic Sclerosis: Possible Epigenetic Regulators of Endothelial Dysfunction
Background Endothelial dysfunction is a key feature of Systemic sclerosis (SSc). MicroRNAs (miRs) are novel post-transcriptional regulators implicated in SSc pathogenesis. MiR-34a and miR-155 are related to endothelial senescence and inflammation. Objectives To investigate the expression of miR-34a and miR-155 in peripheral blood mononuclear cells (PBMCs) in SSc. Methods Twenty-seven consecutive patients with Raynaud phenomenon (RP) were enrolled in this exploratory study. Patients were divided into 3 different groups: SSc patients fulfilling the 1987 ACR criteria (n=10), SSc patients fulfilling the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) criteria (n=9) and patients with primary RP (n=8). Matched healthy controls (HC) (n=7) were enrolled. Expression of miR-34a and miR-155 was evaluated by qPCR on PBMCs isolated by gradient hystopaque technique from peripheral blood (PB) of all patients. Using HumanTargetScan cross-referenced methodology, IL-6 receptor (IL6-R) was selected as target of miR-34a and miR-155 while VEGF-RII as target of miR-155. Targets were experimentally confirmed by qPCR. VEGF, VEGF-RII, IL-6 and IL-6R plasma levels were determined by ELISA. Results MiR-155 is overexpressed either in VEDOSS (p=0.0002) and SSc (p=0.04) patients compared to HC. MiR-34a expression is increased only in SSc compared to HC (p=0.01). Patients with primary RP did not differ according to miR-155 and miR-34a expression from HC (p>0.05). IL-6R and VEGF-RII expression is significantly lower in SSc and VEDOSS patients compared to primary RP (p=0.03 and p=0.03). Moreover, IL-6R/miR-155 and VEGF-RII/miR-155 ratios were significantly lower in SSc and VEDOSS compared to primary RP (pConclusions MiR-34a and miR-155 expression is unbalanced in SSc and VEDOSS acting on IL-6/IL-6R and VEGF/VEGF-RII pathways. This contributes to a decreased expression of IL-6R and VEGF-RII associated to the increase of IL-6 and VEGF plasma levels characterizing different disease clinical features. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.4461
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 352
THU0488 Microrna-34A and Microrna-155 Unbalance is Associated to IL-6/IL-6R and Vegf/Vegf-Rii Pathways in VEDOSS and Long Standing Systemic Sclerosis: Possible Epigenetic Regulators of Endothelial Dysfunction
Background Endothelial dysfunction is a key feature of Systemic sclerosis (SSc). MicroRNAs (miRs) are novel post-transcriptional regulators implicated in SSc pathogenesis. MiR-34a and miR-155 are related to endothelial senescence and inflammation. Objectives To investigate the expression of miR-34a and miR-155 in peripheral blood mononuclear cells (PBMCs) in SSc. Methods Twenty-seven consecutive patients with Raynaud phenomenon (RP) were enrolled in this exploratory study. Patients were divided into 3 different groups: SSc patients fulfilling the 1987 ACR criteria (n=10), SSc patients fulfilling the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) criteria (n=9) and patients with primary RP (n=8). Matched healthy controls (HC) (n=7) were enrolled. Expression of miR-34a and miR-155 was evaluated by qPCR on PBMCs isolated by gradient hystopaque technique from peripheral blood (PB) of all patients. Using HumanTargetScan cross-referenced methodology, IL-6 receptor (IL6-R) was selected as target of miR-34a and miR-155 while VEGF-RII as target of miR-155. Targets were experimentally confirmed by qPCR. VEGF, VEGF-RII, IL-6 and IL-6R plasma levels were determined by ELISA. Results MiR-155 is overexpressed either in VEDOSS (p=0.0002) and SSc (p=0.04) patients compared to HC. MiR-34a expression is increased only in SSc compared to HC (p=0.01). Patients with primary RP did not differ according to miR-155 and miR-34a expression from HC (p>0.05). IL-6R and VEGF-RII expression is significantly lower in SSc and VEDOSS patients compared to primary RP (p=0.03 and p=0.03). Moreover, IL-6R/miR-155 and VEGF-RII/miR-155 ratios were significantly lower in SSc and VEDOSS compared to primary RP (pConclusions MiR-34a and miR-155 expression is unbalanced in SSc and VEDOSS acting on IL-6/IL-6R and VEGF/VEGF-RII pathways. This contributes to a decreased expression of IL-6R and VEGF-RII associated to the increase of IL-6 and VEGF plasma levels characterizing different disease clinical features. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.4461